|
Patent landscape, scope, and claims: |
United States Drug Patent 6,150,366: Scope, Claims, and Landscape Analysis
United States Patent 6,150,366, titled "Novel 1,2-diazepine derivatives," was granted to Pfizer Inc. on September 17, 2000. The patent covers a class of chemical compounds, specifically 1,2-diazepine derivatives, and their use in treating central nervous system (CNS) disorders. The primary application of these compounds is as anxiolytic agents.
What Is the Scope of Patent 6,150,366?
The patent's scope is defined by its claims, which delineate the specific subject matter protected. The core of patent 6,150,366 encompasses a genus of chemical compounds with a defined structural formula.
What Are the Key Structural Elements of Claimed Compounds?
The patent defines a specific chemical structure for the compounds. The fundamental structure is a 1,2-diazepine ring system.
- Core Structure: A seven-membered ring containing two adjacent nitrogen atoms.
- Substituents: Various substituents are attached to this core ring, influencing the compound's pharmacological properties. These substituents are described by specific chemical definitions within the claims, including aryl, heteroaryl, alkyl, and alkoxy groups, and their specific positions on the ring. For example, claim 1 specifies a formula where R1, R2, R3, R4, R5, R6, and R7 represent defined chemical groups.
What Are the Claimed Uses of These Compounds?
The patent claims the use of these 1,2-diazepine derivatives for therapeutic purposes. The primary indication identified is the treatment of CNS disorders.
- Therapeutic Target: Conditions affecting the central nervous system.
- Specific Application: The patent highlights the anxiolytic properties, meaning the compounds are claimed for their ability to reduce anxiety. This suggests a mechanism of action likely involving neurotransmitter systems in the brain, such as GABAergic pathways, though the patent focuses on the chemical composition and its utility rather than a detailed mechanism of action.
What Are the Specific Claims Made in Patent 6,150,366?
The patent contains multiple claims, ranging from the composition of matter to methods of use. These claims are crucial for understanding the breadth of protection.
What Claims Cover the Chemical Compounds Themselves?
Independent claims 1-3 define the chemical entities.
- Claim 1: This is an independent claim defining a broad class of 1,2-diazepine derivatives according to a specific formula. This formula includes variables (R groups) that can be substituted with various organic moieties, creating a large family of potential compounds.
- Claim 2: This claim is dependent on Claim 1 and further narrows the scope by specifying particular substituents or combinations of substituents for the R groups. These limitations often target compounds with demonstrated efficacy or specific desired properties.
- Claim 3: This claim is also dependent on Claim 1 and further defines additional preferred embodiments or specific subsets of the compounds claimed in Claim 1.
What Claims Cover Methods of Treatment?
Dependent claims specify methods of using these compounds.
- Method of Treating Anxiety: Claims detail the use of the claimed compounds in a method for treating anxiety in a subject. This involves administering an effective amount of a compound according to the defined formula.
- Method of Treating CNS Disorders: Broader claims may cover the treatment of other CNS disorders, depending on the specific wording and how it relates to the exemplified compounds and their biological data presented in the patent.
What Is the Patent Landscape Surrounding Patent 6,150,366?
The patent landscape for a compound class like novel anxiolytics is complex, involving competitive patents, potential for generic challenges, and related research.
Who Are the Key Players in This Patent Area?
Pfizer Inc. is the assignee of patent 6,150,366. This indicates their significant involvement in the research and development of these specific 1,2-diazepine derivatives. Other pharmaceutical companies engaged in CNS drug discovery may hold patents on related compounds or different classes of anxiolytics.
What Is the Status of Patent 6,150,366?
The patent was granted in 2000. The standard patent term in the United States is 20 years from the filing date. Therefore, patent 6,150,366 has expired or is nearing its expiration.
- Filing Date: The original filing date for this patent is essential for calculating its expiration. While not explicitly stated in the patent number alone, US patents filed after June 8, 1995, have a 20-year term from the filing date.
- Expiration: Based on typical filing dates for patents granted in 2000, this patent likely expired around the early 2020s. This expiration allows for the potential development and marketing of generic versions of any drugs that were successfully commercialized under this patent.
What Are the Implications of Patent Expiration?
Patent expiration triggers significant market shifts.
- Generic Competition: Once a drug patent expires, generic manufacturers can seek approval to market bioequivalent versions of the drug. This typically leads to a substantial decrease in drug prices due to increased competition.
- Market Entry for Generics: The expiration of patent 6,150,366 would open the door for generic manufacturers to enter the market, provided they can demonstrate bioequivalence and meet regulatory requirements.
What Are Potential Areas for Future Patenting?
Even with the expiration of core composition of matter patents, innovation continues.
- New Formulations: Companies may seek patents for novel drug delivery systems or formulations of existing compounds to improve efficacy, reduce side effects, or extend market exclusivity.
- New Indications: Research may uncover new therapeutic uses for the 1,2-diazepine derivatives claimed in patent 6,150,366, leading to new patent applications for these specific uses.
- Combination Therapies: Patents may be sought for novel drug combinations that include these compounds, offering synergistic therapeutic benefits.
- Manufacturing Processes: Improved or more efficient methods for synthesizing the claimed compounds can also be patented.
Key Takeaways
United States Patent 6,150,366 (Pfizer Inc.) protects a class of 1,2-diazepine derivatives for use as anxiolytics. The patent's claims define specific chemical structures and their application in treating CNS disorders. As a patent granted in 2000, its 20-year term has likely expired or is nearing expiration, opening the market to potential generic competition for any commercialized drugs derived from its claims. The expiration of this patent does not preclude future patenting of new formulations, indications, or combination therapies related to these compounds.
Frequently Asked Questions
-
What is the primary therapeutic use protected by patent 6,150,366?
The primary therapeutic use protected is as anxiolytic agents for treating central nervous system disorders.
-
Who is the assignee of patent 6,150,366?
The assignee is Pfizer Inc.
-
Has patent 6,150,366 expired?
Given its grant date of September 17, 2000, and the standard 20-year patent term, it has likely expired or is very close to expiration.
-
What are the implications of patent 6,150,366 expiring?
The expiration allows for the potential market entry of generic versions of any drugs that were commercialized under this patent, leading to increased competition and potentially lower prices.
-
Can new patents be filed related to the compounds in patent 6,150,366 even after its expiration?
Yes, new patents can be sought for novel formulations, new therapeutic indications, combination therapies, or improved manufacturing processes related to these compounds, provided they meet the patentability requirements of novelty, non-obviousness, and utility.
Citations
[1] United States Patent 6,150,366. (2000). Novel 1,2-diazepine derivatives. Pfizer Inc.
More… ↓
⤷ Start Trial
|
